Skip to main content
NADFaq.com

Benefit

Liver & Hepatic Metabolism

NAFLD/MASLD, alcohol metabolism, and SIRT1 in the liver.

Emerging human evidence

Hepatic NAD+ falls in high-fat-diet and alcohol-exposure models, and SIRT1 deacetylation of SREBP-1c and PGC-1α regulates lipogenesis and mitochondrial β-oxidation in hepatocytes. NR and NMN reduce steatosis and improve insulin sensitivity in rodent models of NAFLD/MASLD. Small human trials in NAFLD and alcoholic liver disease are ongoing; cleanly positive hepatic endpoints in humans remain limited.

Key studies

  1. Cell Metabolism · 2011 · PMID 21982712

    Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

    Yoshino J, et al.

  2. Cell Metabolism · 2012 · PMID 22682224

    The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity

    Cantó C, et al.

    Read summary

  3. Science · 2016 · PMID 27127236

    NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice

    Zhang H, et al.

    Read summary

Editorial note

NADFaq grades evidence on a 4-tier scale based on human trial quality, sample size, reproducibility, and mechanistic plausibility. This is a conservative framework — many published benefits of NAD+ precursors rest on preclinical (rodent or cell) work that has not yet translated to humans.

How we grade evidence